Home › Small Cell Lung Cancer › Illinois › Chicago
Small Cell Lung Cancer clinical trials in Chicago, IL
13 studies for Small Cell Lung Cancer are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RecruitingPhase 1/2
- University of Chicago, Chicago
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
RecruitingPhase 2
- University of Illinois Chicago, Chicago
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
RecruitingPhase 1/2
- University of Chicago ( Site 1108), Chicago
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
RecruitingPhase 1
- The University of Chicago, Chicago
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
RecruitingPhase 3
- University of Chicago Medical Center /ID# 280149, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Northwestern University Feinberg School of Medicine, Chicago
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
RecruitingPhase 2
- Northwestern, Chicago
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RecruitingPhase 3
- Rush MD Anderson Cancer Center, Chicago
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
RecruitingPhase 1
- University of Illinois Chicago, Chicago
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
RecruitingPhase 2
- University of Illinois Cancer Center, Chicago
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
RecruitingPhase 2
- Northwestern University, Chicago
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
RecruitingPhase 1/2
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RecruitingPhase 2
- University of Chicago Medicine, Chicago
Small Cell Lung Cancer trials in other cities
- Houston, TX26 studies
- New York City, NY23 studies
- Arlington, VA22 studies
- Boston, MA22 studies
- Los Angeles, CA20 studies
- Nashville, TN20 studies
- Orlando, FL14 studies
- Cleveland, OH13 studies
- Dallas, TX13 studies
- St. Louis, MO13 studies
- Washington, DC13 studies
- Detroit, MI12 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.